Anatara Lifesciences Ltd

Equities

ANR

AU000000ANR0

Pharmaceuticals

Market Closed - Australian S.E. 02:10:44 2024-04-26 am EDT 5-day change 1st Jan Change
0.048 AUD +4.35% Intraday chart for Anatara Lifesciences Ltd +23.08% +118.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial MT
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Anatara Lifesciences Raised Nealy AU$960,000 Via Entitlement Offer MT
Anatara Lifesciences Ltd Announces Board Changes CI
Anatara Lifesciences to Proceed to Stage II of IBS Drug Trial MT
Anatara Lifesciences Finalizes Patients for Irritable Bowel Syndrome Clinical Trial Stage One MT
Anatara Lifesciences Ltd Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Anatara Lifesciences Receives R&D Tax Rebate; Shares Up 3% MT
Anatara Lifesciences Ltd Announces Registered Office Change CI
Anatara Lifesciences Provides Update on the Gastrointestinal Reprogramming(Garp) Trial for IBS CI
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Anatara Lifesciences Ltd Announces board Changes CI
Anatara Lifesciences Raising Funds for Patient Trial, Future Project Acquisitions MT
Anatara Lifesciences Receives More than $310,000 R&D Tax Rebate MT
CSIRO Halts Psychological Functioning Trial for Dietary Supplement MT
Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial CI
Anatara Lifesciences Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Anatara Lifesciences Modifies Protocol for Upccoming Gastrointestinal Disease Trial MT
Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer CI
Anatara Lifesciences Limited Announces to Provide an Update on the Progress of Clinical Trials in Irritable Bowel Syndrome and Psychological Functioning CI
Anatara Lifesciences Expands Criteria for Irritable Bowel Trial MT
Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype CI
Anatara Lifesciences CEO to Step Down MT
Anatara Lifesciences Limited Announces Chief Executive Officer Changes CI
Anatara Lifesciences Provides Clinical Trials Update CI
Chart Anatara Lifesciences Ltd
More charts
Anatara Lifesciences Ltd is an Australia-based life sciences company. The Company is engaged in developing evidence-based solutions for gastrointestinal diseases in humans and animals. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.
More about the company
  1. Stock Market
  2. Equities
  3. ANR Stock
  4. News Anatara Lifesciences Ltd
  5. Anatara Lifesciences Receives R&D Tax Rebate; Shares Up 3%